Mackenzie Financial Corp Buys 43,630 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mackenzie Financial Corp grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 535,557 shares of the biopharmaceutical company’s stock after acquiring an additional 43,630 shares during the period. Mackenzie Financial Corp’s holdings in Gilead Sciences were worth $43,385,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Gilead Sciences by 324.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the period. Morgan Stanley lifted its holdings in shares of Gilead Sciences by 11.5% during the fourth quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after purchasing an additional 1,780,489 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 14.8% during the third quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock worth $951,350,000 after purchasing an additional 1,987,058 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 3.0% during the first quarter. Northern Trust Corp now owns 14,969,251 shares of the biopharmaceutical company’s stock worth $889,922,000 after purchasing an additional 430,810 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 0.6 %

NASDAQ:GILD opened at $67.31 on Wednesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm has a 50-day moving average of $72.40 and a 200-day moving average of $76.73. The company has a market cap of $83.81 billion, a PE ratio of 14.96, a PEG ratio of 0.86 and a beta of 0.19. Gilead Sciences, Inc. has a one year low of $67.18 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The business had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.67 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.58%. Gilead Sciences’s payout ratio is presently 68.44%.

Analyst Ratings Changes

A number of equities analysts have recently commented on GILD shares. Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Finally, Mizuho dropped their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $85.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.